Cardiopulmonary bypass-associated pulmonary injury is a common complication after infant cardiac surgery and may contribute to impaired oxygenation, prolonged mechanical ventilation, and longer intensive care stay. Lidocaine has anti-inflammatory and membrane-stabilizing properties and may attenuate perioperative lung injury. This investigator-initiated, randomized, placebo-controlled, double-blind trial will evaluate whether perioperative intravenous lidocaine reduces postoperative pulmonary injury in infants undergoing corrective non-palliative congenital cardiac surgery with cardiopulmonary bypass.
Infants aged 0 to 12 months.
Congenital heart disease requiring corrective, non-palliative cardiac surgery with cardiopulmonary bypass.
American Society of Anesthesiologists (ASA) physical status I to III.
Written informed consent provided by parent(s) or legal guardian(s).
Multiple malformations, chromosomal abnormalities, or immunodeficiency.
Known or suspected allergy to lidocaine.
Concomitant continuous infusion of another local anesthetic.
Conditions associated with increased risk of lidocaine accumulation or toxicity, including severe conduction block or severe bradycardia.